Branded Drug Makers Face Increasingly Aggressive Challenges By Generic Makers, Study Finds

Law360, New York (May 31, 2005, 12:00 AM EDT) -- Makers of branded drugs are increasingly turning to patent litigation to defend their blockbuster drugs, a new survey has found.

Patent litigation remains the most commonly used generic defense strategy among makers of branded drugs, with 71% of drug companies reporting legal disputes to defend their patents in the past three years, according to research from pharmaceutical business intelligence firm Cutting Edge Information.

“The pharmaceutical industry faces a significant threat from generics companies who challenge existing patents and erode branded product sales. While patent defense constitutes...
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.